A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

<p>Abstract</p> <p>Background</p> <p>Anti-angiogenic treatment is believed to have at least cystostatic effects in highly vascularized tumours like pancreatic cancer. In this study, the treatment effects of the angiogenesis inhibitor Cilengitide and gemcitabine were com...

Full description

Bibliographic Details
Main Authors: Katz Frieder, Balcke Peter, Hawkins Robert, Scheithauer Werner, Dobrowolski Frank, Piedbois Pascal, Herzog Peter, Neyns Bart, Stöger Herbert, Hossfeld Dieter K, Dittrich Christian, Niedergethmann Marco, Raedle Jochen, Oettle Helmut, Langrehr Jan M, Friess Helmut, Vermorken Jan, van Belle Simon, Davidson Neville, Esteve Albert, Castellano Daniel, Kleeff Jörg, Tempia-Caliera Adrien A, Kovar Andreas, Nippgen Johannes
Format: Article
Language:English
Published: BMC 2006-12-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/6/285

Internet

http://www.biomedcentral.com/1471-2407/6/285

Similar Items